Exploring with [18F]UCB-H the in vivo Variations in SV2A Expression through the Kainic Acid Rat Model of Temporal Lobe Epilepsy

Research output: Contribution to journalArticle

Standard

Exploring with [18F]UCB-H the in vivo Variations in SV2A Expression through the Kainic Acid Rat Model of Temporal Lobe Epilepsy. / Serrano, Maria Elisa; Bahri, Mohamed Ali; Becker, Guillaume; Seret, Alain; Germonpré, Charlotte; Lemaire, Christian; Giacomelli, Fabrice; Mievis, Frédéric; Luxen, André; Salmon, Eric; Rogister, Bernard; Raedt, Robrecht; Plenevaux, Alain.

In: Molecular imaging and biology, 23.03.2020, p. 1-11.

Research output: Contribution to journalArticle

Harvard

Serrano, ME, Bahri, MA, Becker, G, Seret, A, Germonpré, C, Lemaire, C, Giacomelli, F, Mievis, F, Luxen, A, Salmon, E, Rogister, B, Raedt, R & Plenevaux, A 2020, 'Exploring with [18F]UCB-H the in vivo Variations in SV2A Expression through the Kainic Acid Rat Model of Temporal Lobe Epilepsy', Molecular imaging and biology, pp. 1-11. https://doi.org/10.1007/s11307-020-01488-7

APA

Serrano, M. E., Bahri, M. A., Becker, G., Seret, A., Germonpré, C., Lemaire, C., ... Plenevaux, A. (2020). Exploring with [18F]UCB-H the in vivo Variations in SV2A Expression through the Kainic Acid Rat Model of Temporal Lobe Epilepsy. Molecular imaging and biology, 1-11. https://doi.org/10.1007/s11307-020-01488-7

Vancouver

Author

Serrano, Maria Elisa ; Bahri, Mohamed Ali ; Becker, Guillaume ; Seret, Alain ; Germonpré, Charlotte ; Lemaire, Christian ; Giacomelli, Fabrice ; Mievis, Frédéric ; Luxen, André ; Salmon, Eric ; Rogister, Bernard ; Raedt, Robrecht ; Plenevaux, Alain. / Exploring with [18F]UCB-H the in vivo Variations in SV2A Expression through the Kainic Acid Rat Model of Temporal Lobe Epilepsy. In: Molecular imaging and biology. 2020 ; pp. 1-11.

Bibtex - Download

@article{e1a2ec6f07ef49d9a93a2f39d2263ef7,
title = "Exploring with [18F]UCB-H the in vivo Variations in SV2A Expression through the Kainic Acid Rat Model of Temporal Lobe Epilepsy",
abstract = "Purpose: The main purpose of this study was to understand how the positron emission tomography (PET) measure of the synaptic vesicle 2A (SV2A) protein varies in vivo during the development of temporal lobe epilepsy (TLE) in the kainic acid rat model. Procedures: Twenty Sprague Dawley male rats were administered with multiple systemic doses of saline (control group, n = 5) or kainic acid (5 mg/kg/injection, epileptic group, n = 15). Both groups were scanned at the four phases of TLE (early, latent, transition, and chronic phase) with the [18F]UCB-H PET radiotracer and T2-structural magnetic resonance imaging. At the end of the scans (3 months post-status epilepticus), rats were monitored for 7 days with electroencephalography for the detection of spontaneous electrographic seizures. Finally, the immunofluorescence staining for SV2A expression was performed. Results: Control rats presented a significant increase in [18F]UCB-H binding at the last two scans, compared with the first ones (p < 0.001). This increase existed but was lower in epileptic animals, producing significant group differences in all the phases of the disease (p < 0.028). Furthermore, the quantification of the SV2A expression in vivo with the [18F]UCB-H radiotracer or ex vivo with immunofluorescence led to equivalent results, with a positive correlation between both. Conclusions: Even if further studies in humans are required, the ability to detect a progressive decrease in SV2A expression during the development of temporal lobe epilepsy supports the use of [18F]UCB-H as a useful tool to differentiate, in vivo, between healthy and epileptic animals along with the development of the epileptic disease.",
keywords = "Temporal lobe epilepsy, Kainic acid, SV2A, [18F]UCB-H, EEG, SV2A immunofluorescence, T2 MRI",
author = "Serrano, {Maria Elisa} and Bahri, {Mohamed Ali} and Guillaume Becker and Alain Seret and Charlotte Germonpr{\'e} and Christian Lemaire and Fabrice Giacomelli and Fr{\'e}d{\'e}ric Mievis and Andr{\'e} Luxen and Eric Salmon and Bernard Rogister and Robrecht Raedt and Alain Plenevaux",
note = "Score=10",
year = "2020",
month = "3",
day = "23",
doi = "10.1007/s11307-020-01488-7",
language = "English",
pages = "1--11",
journal = "Molecular imaging and biology",
issn = "1536-1632",
publisher = "Springer Verlag",

}

RIS - Download

TY - JOUR

T1 - Exploring with [18F]UCB-H the in vivo Variations in SV2A Expression through the Kainic Acid Rat Model of Temporal Lobe Epilepsy

AU - Serrano, Maria Elisa

AU - Bahri, Mohamed Ali

AU - Becker, Guillaume

AU - Seret, Alain

AU - Germonpré, Charlotte

AU - Lemaire, Christian

AU - Giacomelli, Fabrice

AU - Mievis, Frédéric

AU - Luxen, André

AU - Salmon, Eric

AU - Rogister, Bernard

AU - Raedt, Robrecht

AU - Plenevaux, Alain

N1 - Score=10

PY - 2020/3/23

Y1 - 2020/3/23

N2 - Purpose: The main purpose of this study was to understand how the positron emission tomography (PET) measure of the synaptic vesicle 2A (SV2A) protein varies in vivo during the development of temporal lobe epilepsy (TLE) in the kainic acid rat model. Procedures: Twenty Sprague Dawley male rats were administered with multiple systemic doses of saline (control group, n = 5) or kainic acid (5 mg/kg/injection, epileptic group, n = 15). Both groups were scanned at the four phases of TLE (early, latent, transition, and chronic phase) with the [18F]UCB-H PET radiotracer and T2-structural magnetic resonance imaging. At the end of the scans (3 months post-status epilepticus), rats were monitored for 7 days with electroencephalography for the detection of spontaneous electrographic seizures. Finally, the immunofluorescence staining for SV2A expression was performed. Results: Control rats presented a significant increase in [18F]UCB-H binding at the last two scans, compared with the first ones (p < 0.001). This increase existed but was lower in epileptic animals, producing significant group differences in all the phases of the disease (p < 0.028). Furthermore, the quantification of the SV2A expression in vivo with the [18F]UCB-H radiotracer or ex vivo with immunofluorescence led to equivalent results, with a positive correlation between both. Conclusions: Even if further studies in humans are required, the ability to detect a progressive decrease in SV2A expression during the development of temporal lobe epilepsy supports the use of [18F]UCB-H as a useful tool to differentiate, in vivo, between healthy and epileptic animals along with the development of the epileptic disease.

AB - Purpose: The main purpose of this study was to understand how the positron emission tomography (PET) measure of the synaptic vesicle 2A (SV2A) protein varies in vivo during the development of temporal lobe epilepsy (TLE) in the kainic acid rat model. Procedures: Twenty Sprague Dawley male rats were administered with multiple systemic doses of saline (control group, n = 5) or kainic acid (5 mg/kg/injection, epileptic group, n = 15). Both groups were scanned at the four phases of TLE (early, latent, transition, and chronic phase) with the [18F]UCB-H PET radiotracer and T2-structural magnetic resonance imaging. At the end of the scans (3 months post-status epilepticus), rats were monitored for 7 days with electroencephalography for the detection of spontaneous electrographic seizures. Finally, the immunofluorescence staining for SV2A expression was performed. Results: Control rats presented a significant increase in [18F]UCB-H binding at the last two scans, compared with the first ones (p < 0.001). This increase existed but was lower in epileptic animals, producing significant group differences in all the phases of the disease (p < 0.028). Furthermore, the quantification of the SV2A expression in vivo with the [18F]UCB-H radiotracer or ex vivo with immunofluorescence led to equivalent results, with a positive correlation between both. Conclusions: Even if further studies in humans are required, the ability to detect a progressive decrease in SV2A expression during the development of temporal lobe epilepsy supports the use of [18F]UCB-H as a useful tool to differentiate, in vivo, between healthy and epileptic animals along with the development of the epileptic disease.

KW - Temporal lobe epilepsy

KW - Kainic acid

KW - SV2A, [18F]UCB-H

KW - EEG

KW - SV2A immunofluorescence

KW - T2 MRI

UR - https://ecm.sckcen.be/OTCS/llisapi.dll/overview/39028608

U2 - 10.1007/s11307-020-01488-7

DO - 10.1007/s11307-020-01488-7

M3 - Article

SP - 1

EP - 11

JO - Molecular imaging and biology

JF - Molecular imaging and biology

SN - 1536-1632

ER -

ID: 6834020